Novo Nordisk Investor Presentation - First Nine Months of 2016

Investor presentation First nine months of 2016 Slide 74 Oral semaglutide dose dependently reduced HbA1c and body weight in a 26-week phase 2 trial in type 2 diabetes HbA1c reduction from a mean baseline of 7.9% - Placebo HbA1c (%) 8.0 Sema 2.5 mg - Sema 5 mg Sema 10 mg Weight loss from a mean base line of 92 kg - Sema 20 mg Sema 40 mg - Sema 1 mg sc Weight loss (kg) 0.0 7.5 7.0 6.5 6.0 -2.0 -4.0 -6.0 0.0 -8.0 0 2 4 6 8 10 12 14 16 18 20 22 24 26 Time (weeks) 0 2 4 6 8 10 12 14 16 18 20 22 24 26 Time (weeks) Inclusion criteria: Type 2 diabetes; 7.0% HbA 1c 9.5%; treatment with diet and exercise with or without metformin; sc: subcutaneous; sema: semaglutide changing diabetes® novo nordisk

View entire presentation